Milbotyl 300mg/ml Solution for Injection for Cattle and Sheep 50ml.
Cattle Treatment of bovine respiratory disease associated with Mannheimia haemolytica and Pasteurella multocida.
For the treatment of interdigital necrobacillosis.
Sheep For the treatment of respiratory tract infections caused by Mannheimia haemolytica and Pasteurella multocida.
Treatment of foot rot in sheep caused by Dichelobacter nodosus and Fusobacterium necrophorum.
Treatment of acute ovine mastitis caused by Staphylococcus aureus and Mycoplasma agalactiae.
Dosage and administration:
FOR SUBCUTANEOUS INJECTION ONLY.
Use 10 mg tilmicosin per kg body weight (corresponding to 1 ml of Milbotyl per 30 kg bodyweight).
Cattle: Withdraw the required dose from the vial and remove the syringe from the needle, leaving the needle in the vial.
When a group of animals has to be treated, leave the needle in the vial to remove the subsequent doses. Restrain the animal and insert a separate needle subcutaneously at the injection site, preferably in a skinfold over the rib cage behind the shoulder. Attach the syringe to the needle and inject into the base of the skinfold. Do not inject more than 20 ml per injection site.
Sheep: Accurate weighing of lambs is important to avoid overdosing. The use of a 2 ml or smaller syringe improves accurate dosing. Withdraw the required dose from the vial and remove the syringe from the needle, leaving the needle in the vial. Restrain the sheep whilst leaning over the animal and insert a separate needle subcutaneously into the injection site, which should be in a skinfold over the rib cage behind the shoulder. Attach the syringe to the needle and inject into the base of the skin fold. Do not inject more than 2 ml per injection.
Advice on correct administration:
Official, national and regional antimicrobial policies should be taken into account when the product is used.
To avoid self-injection do not use automatic injection equipment. The use of the product should be based on susceptibility tests.
If no improvement is noted within 48 hours, the diagnosis should be confirmed. Avoid introduction of contamination into vial during use. Do not use Milbotyl if you notice any foreign particulate matter and/or abnormal physical appearance. In the event of either being observed, discard the vial.
Contra-indications, warnings, etc:
Do not administer intravenously. Do not administer intramuscularly. Do not administer to lambs weighing less than 15 kg.
Do not administer to primates. Do not administer to pigs. Do not administer to horses and donkeys. Do not administer to goats.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Occasionally, a soft diffuse swelling may occur at the injection site but this disappears within five to eight days. In rare cases, recumbency, incoordination and convulsions have been observed.
Deaths of cattle have been observed following a single intravenous dose of 5 mg/kg, and following the subcutaneous injection of doses of 150 mg/kg at 72 hour intervals. In pigs, intramuscular injection at 20 mg/kg has caused deaths. Sheep have died following a single intravenous injection of 7.5 mg/kg bodyweight.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Special precautions for use in animals:
Sheep: The clinical trials did not demonstrate a bacteriological cure in sheep with acute mastitis caused by Staphyloccocus aureus and Mycoplasma agalactiae. Do not administer to lambs weighing less than 15 kg since there is a risk of overdose toxicity. Accurate weighing of lambs is important to avoid overdose. The use of a 2 ml or smaller syringe improves accurate dosing.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
INJECTION OF THIS DRUG IN HUMANS CAN BE FATAL - EXERCISE EXTREME CAUTION TO AVOID ACCIDENTAL SELF-INJECTION AND FOLLOW THE ADMINISTRATION INSTRUCTIONS AND THE GUIDANCE BELOW, PRECISELY
This product should only be administered by a veterinary surgeon. Never carry a syringe loaded with MILBOTYL 300 mg/ml SOLUTION FOR INJECTION with the needle attached. The needle should be connected to the syringe only when filling the syringe or administering the injection. Keep the syringe and needle separate at all other times. Do not use automatic injection equipment. Ensure that animals are properly restrained, including those in the vicinity. Do not work alone when using MILBOTYL 300 mg/ml SOLUTION FOR INJECTION. In case of human injection SEEK IMMEDIATE MEDICAL ATTENTION and take the vial or the package leaflet with you. Apply a cold pack (not ice) directly to the injection site.
Additional operator safety warnings:
Avoid contact with eyes. Rinse any splashes from skin or eyes immediately with water.
May cause sensitisation by skin contact. Wash hands after use.
Note to the physician:
INJECTION OF THIS DRUG IN HUMANS HAS BEEN ASSOCIATED WITH FATALITIES
The cardiovascular system is the target of toxicity, and this toxicity may be due to calcium channel blockade. Administration of intravenous calcium chloride should only be considered if there is positive confirmation of exposure to tilmicosin.
In dog studies, tilmicosin induced a negative inotropic effect with consequent tachycardia, and a reduction in systemic arterial blood pressure and arterial pulse pressure. DO NOT GIVE ADRENALIN OR BETA-ADRENERGIC ANTAGONISTS SUCH AS PROPRANOLOL. In pigs, tilmicosin-induced lethality is potentiated by adrenalin. In dogs, treatment with intravenous calcium chloride showed a positive effect on the left ventricular inotropic state and some improvements in vascular blood pressure and tachycardia. Pre-clinical data and an isolated clinical report suggest that calcium chloride infusion may help to reverse tilmicosin induced changes in blood pressure and heart rate in humans. Administration of dobutamine should also be considered due to its positive inotropic effects although it does not influence tachycardia. As tilmicosin persists in tissues for several days, the cardiovascular system should be closely monitored and supportive treatment provided. Physicians treating patients exposed to this compound are advised to discuss clinical management with the National Poison Information Service on: 018379964 (IE) or 0844 892 0111(UK).
The safety of the veterinary medicinal product has not been established during pregnancy. Use only according to the benefit/risk assessment by the responsible veterinarian.
Interactions with other medicinal products and other forms of interaction:
Interactions between macrolides and ionophores have been observed in some species.
Overdose (symptoms, emergency procedures, antidotes):
In cattle subcutaneous injections of 10, 30 and 50 mg/kg body weight, repeated three times with a 72 hours interval, did not cause death. As expected, oedema developed at the site of injection. The only lesion observed at autopsy was a necrosis of the myocardium in the group treated with 50 mg/kg body weight. Doses of 150 mg/kg body weight, administered subcutaneously with an interval of 72 hours caused death. Oedema at the site of injection was observed and at autopsy a light necrosis of the myocardium was the only lesion determined. Other symptoms observed were: difficulty in moving, reduced appetite and tachycardia. In sheep single injections (approximately 30 mg/kg body weight) may cause a slight increase of the rate of respiration.
Higher doses (150 mg/kg body weight) caused ataxia, lethargy and the inability to raise the head. Deaths occurred after one single intravenous injection of 5 mg/kg body weight in cattle and 7.5 mg/kg in sheep body weight.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products
Cattle: Meat and offal: 70 days. Milk: 36 days
If the product is administered to cows during the dry period or to pregnant dairy heifers, milk should not be used for human consumption until 36 days after calving.
Sheep: Meat and offal: 42 days. Milk: 18 days
If the product is administered to ewes during the dry period or to pregnant ewes, milk should not be used for human consumption until 18 days after lambing.
Keep out of the sight and reach of children.
Do not store above 30°C Protect from direct sunlight.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Shelf life after first opening the container: 28 days. When the container is broached (opened) for the first time, using the in-use shelf-life which is specified on this datasheet, the date on which any product remaining in the carton should be discarded should be worked out. This discard date should be written in the space provided.
50 ml or 100 ml vials. Not all pack sizes may be marketed.
Free shipping from Hyperdrug
|Over £49.00||Any Weight||FREE*|
|Under £49.00||Under 250g||£2.49|
|Under £49.00||No weight limit||£4.99|
Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited delivery options are available.
Estimated " Usually shipped in" information is shown against most products
Postage outside of the UK is from £4.95
Finding out delivery Charges and options before checkout
- Simply add an item to your basket
- Click view basket/Cart
- Click estimate shipping charges
*Free delivery and selected charges on orders over £49.00 mainland UK Parcelforce Zone1 for more information check the delivery info page.